You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

TEVETEN HCT Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Teveten Hct, and when can generic versions of Teveten Hct launch?

Teveten Hct is a drug marketed by Abbvie and is included in one NDA.

The generic ingredient in TEVETEN HCT is eprosartan mesylate; hydrochlorothiazide. There are eleven drug master file entries for this compound. Additional details are available on the eprosartan mesylate; hydrochlorothiazide profile page.

Summary for TEVETEN HCT
US Patents:0
Applicants:1
NDAs:1
Raw Ingredient (Bulk) Api Vendors: 2
Clinical Trials: 3
Patent Applications: 8
Formulation / Manufacturing:see details
What excipients (inactive ingredients) are in TEVETEN HCT?TEVETEN HCT excipients list
DailyMed Link:TEVETEN HCT at DailyMed
Drug patent expirations by year for TEVETEN HCT
Recent Clinical Trials for TEVETEN HCT

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
AbbottPhase 3
author! et al. BVPhase 3
SynexusPhase 3

See all TEVETEN HCT clinical trials

US Patents and Regulatory Information for TEVETEN HCT

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie TEVETEN HCT eprosartan mesylate; hydrochlorothiazide TABLET;ORAL 021268-001 Nov 1, 2001 DISCN No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Abbvie TEVETEN HCT eprosartan mesylate; hydrochlorothiazide TABLET;ORAL 021268-002 Nov 1, 2001 DISCN No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for TEVETEN HCT

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie TEVETEN HCT eprosartan mesylate; hydrochlorothiazide TABLET;ORAL 021268-001 Nov 1, 2001 ⤷  Try a Trial ⤷  Try a Trial
Abbvie TEVETEN HCT eprosartan mesylate; hydrochlorothiazide TABLET;ORAL 021268-001 Nov 1, 2001 ⤷  Try a Trial ⤷  Try a Trial
Abbvie TEVETEN HCT eprosartan mesylate; hydrochlorothiazide TABLET;ORAL 021268-002 Nov 1, 2001 ⤷  Try a Trial ⤷  Try a Trial
Abbvie TEVETEN HCT eprosartan mesylate; hydrochlorothiazide TABLET;ORAL 021268-002 Nov 1, 2001 ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Supplementary Protection Certificates for TEVETEN HCT

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0565634 06C0030 France ⤷  Try a Trial PRODUCT NAME: EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE; NAT. REGISTRATION NO/DATE: NL 32075 20060623; FIRST REGISTRATION: LI - 55783 01 20020607
0403159 14/2000 Austria ⤷  Try a Trial PRODUCT NAME: EPROSARTAN, AUCH IN FORM PHARMAZEUTISCH VERTRAEGLICHER SALZE WIE EPROSARTAN MESYLAT; NAT. REGISTRATION NO/DATE: 1-22115, 1-22114, 1-22117 19970930; FIRST REGISTRATION: DE 39573.00.00 - 39573.02.00 19970417
0403159 C300006 Netherlands ⤷  Try a Trial PRODUCT NAME: EPROSARTAN, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER HET MESYLAAT; NAT. REGISTRATION NO/DATE: RVG 22258 - RVG 22260 19980106; FIRST REGISTRATION: DE 39573.00.00 - 39573.00.00 19970417
0565634 91234 Luxembourg ⤷  Try a Trial 91234, EXPIRES: 20161213
0565634 C300115 Netherlands ⤷  Try a Trial PRODUCT NAME: EPROSARTANUM DESGEWENST IN DE VORM VAN EEN; NAT. REGISTRATION NO/DATE: RVG 25926 20020905; FIRST REGISTRATION: RVG 25926 20020905
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.